A Angeliq, Drospirenone CEP of the European Pharmacopoeia monograph is often referred to as a Angeliq, Drospirenone Certificate of Suitability (COS). The purpose of a Angeliq, Drospirenone CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Angeliq, Drospirenone EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Angeliq, Drospirenone to their clients by showing that a Angeliq, Drospirenone CEP has been issued for it. The manufacturer submits a Angeliq, Drospirenone CEP (COS) as part of the market authorization procedure, and it takes on the role of a Angeliq, Drospirenone CEP holder for the record. Additionally, the data presented in the Angeliq, Drospirenone CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Angeliq, Drospirenone DMF.
A Angeliq, Drospirenone CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Angeliq, Drospirenone CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Angeliq, Drospirenone suppliers with CEP (COS) on PharmaCompass.